{
    "clinical_study": {
        "@rank": "142790", 
        "arm_group": [
            {
                "arm_group_label": "AdVance", 
                "description": "Subjects previously implanted with the AdVance Male Sling"
            }, 
            {
                "arm_group_label": "AdVance XP", 
                "description": "Subjects previously implanted with the AdVance XP male sling"
            }
        ], 
        "brief_summary": {
            "textblock": "A single-center retrospective chart review of AdVance and AdVance XP subject data, combined\n      with prospective follow-up of the same subjects to confirm continence, adverse event, and\n      quality of life status. This study includes patients previously implanted with an AdVance or\n      AdVance XP male sling."
        }, 
        "brief_title": "AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Urinary Incontinence, Stress", 
            "Intrinsic Sphincter Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Incontinence", 
                "Urinary Incontinence, Stress"
            ]
        }, 
        "detailed_description": {
            "textblock": "A single-center retrospective chart review of AdVance and AdVance XP subject data, combined\n      with prospective follow-up of the same subjects to confirm continence, adverse event, and\n      quality of life status. This study includes patients previously implanted with an AdVance or\n      AdVance XP male sling."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Valid, written informed consent has been obtained\n\n          2. Male subject \u226540 years of age who received the AdVance male sling after January 1,\n             2010 or the AdVance XP male sling after July 1, 2010 for the treatment of post\n             prostatectomy SUI\n\n          3. Pad use of 1 to 8 pads per day prior to sling placement (subjects who used only a dry\n             prophylactic pad or safety liner at baseline will not be included)\n\n          4. External (distal) sphincter contractility and a coaptive zone of \u2265 1cm confirmed by\n             endoscopic view prior to sling placement\n\n          5. Primary etiology of SUI resulting from radical prostatectomy including, simple open\n             prostatectomy, robotic or laparoscopic prostatectomy\n\n        Exclusion Criteria:\n\n          1. Pad use of more than 8 pads per day prior to sling placement for incontinence\n             management\n\n          2. Urine loss while lying in bed prior to sling placement\n\n          3. Treatment with a urethral sling system, an AMS Sphincter 800\u00ae, or any implanted\n             device for the treatment of urinary incontinence (not including bulking agents) prior\n             to sling placement\n\n          4. TURP procedure prior to sling placement\n\n          5. Urge predominant incontinence prior to sling placement\n\n          6. Past or current neurological disorder (e.g. neurogenic bladder, multiple sclerosis,\n             Parkinson's disease)\n\n          7. History of connective tissue or autoimmune conditions\n\n          8. Past or current condition of compromised immune system\n\n          9. Placement of an inflatable penile prosthesis (IPP) after sling placement\n\n         10. Post void residual of >50 ml prior to sling placement"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Male subject \u226540 years of age who received the AdVance male sling after January 1, 2010 or\n        the AdVance XP male sling after July 1, 2010 for the treatment of post prostatectomy SUI\n        at one institution in Munich, Germany."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725984", 
            "org_study_id": "MC1201"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Male Incontinence", 
            "AdVance Male Sling", 
            "AdVance XP Male Sling", 
            "Male Sling"
        ], 
        "lastchanged_date": "November 9, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Munich", 
                    "country": "Germany", 
                    "state": "Bavaria", 
                    "zip": "81377"
                }, 
                "name": "Ludwig\u2010Maximilians Universit\u00e4t (LMU)"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "2", 
        "official_title": "AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up", 
        "overall_official": {
            "affiliation": "Ludwig\u2010Maximilians Universit\u00e4t (LMU)", 
            "last_name": "Ricarda Bauer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Evaluate the occurrence of all AdVance /AdVance XP device or procedure related adverse events", 
                "measure": "Number of Subjects with device or procedure related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3 Months Post Procedure"
            }, 
            {
                "description": "Evaluate the proportion of subjects with a \u226550% reduction in pads per day use", 
                "measure": "Number of subjects with a \u226550% reduction in pads per day use", 
                "safety_issue": "No", 
                "time_frame": "3 Months Post Procedure"
            }, 
            {
                "description": "Evaluate the proportion of subjects cured (0 pads per day or 1 dry prophylactic pad), improved (not cured and \u226550% reduction in pad use), or failed (not cured and not improved) at the three month and final prospective  follow-up visit", 
                "measure": "Number subjects cured, improved, or failed based on reported pad per day use", 
                "safety_issue": "No", 
                "time_frame": "3 months Post Procedure"
            }, 
            {
                "description": "Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:\n0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);", 
                "measure": "Number of subjects in each pre-defined range of pads per day use", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Evaluate the 24-hour pad weight at the final prospective follow-up visit", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 Months Post Procedure"
            }, 
            {
                "description": "Evaluate the improvement in Quality of Life (Change in quality of life scores as compared to baseline for I-QOL, ICIQ-SF, and summary of values for the PGI-I)", 
                "measure": "Number of subjects with improvement in Quality of Life (Change in quality of life scores as compared to baseline for I-QOL, ICIQ-SF, and summary of values for the PGI-I)", 
                "safety_issue": "No", 
                "time_frame": "3 Months Post Procedure"
            }, 
            {
                "description": "Evaluate the occurrence of all AdVance /AdVance XP device or procedure related adverse events", 
                "measure": "Number of Subjects with device or procedure related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 36 Months Post Procedure"
            }, 
            {
                "description": "Evaluate the proportion of subjects with a \u226550% reduction in pads per day use", 
                "measure": "Number of subjects with a \u226550% reduction in pads per day use", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 Months Post Procedure"
            }, 
            {
                "description": "Evaluate the proportion of subjects cured (0 pads per day or 1 dry prophylactic pad), improved (not cured and \u226550% reduction in pad use), or failed (not cured and not improved) at the three month and final prospective  follow-up visit", 
                "measure": "Number subjects cured, improved, or failed based on reported pad per day use", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months Post Procedure"
            }, 
            {
                "description": "Evaluate the improvement in Quality of Life (Change in quality of life scores as compared to baseline for I-QOL, ICIQ-SF, and summary of values for the PGI-I)", 
                "measure": "Number of subjects with improvement in Quality of Life (Change in quality of life scores as compared to baseline for I-QOL, ICIQ-SF, and summary of values for the PGI-I)", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 Months Post Procedure"
            }, 
            {
                "description": "Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:\n0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);", 
                "measure": "Number of subjects in each pre-defined range of pads per day use", 
                "safety_issue": "No", 
                "time_frame": "3 Months Post Procedure"
            }, 
            {
                "description": "Evaluate the proportion of subjects using the following categories of pads per day at the three month and final prospective follow-up visit:\n0 pads per day or 1 dry prophylactic pad; 1 pad per day; 2 pads per day; 3 pads per day; 4 pads per day; 5 or more pads per day (5, 6, 7, 8 etc. pads per day);", 
                "measure": "Number of subjects in each pre-defined range of pads per day use", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 Months Post Procedure"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725984"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "American Medical Systems", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "American Medical Systems", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "November 2012"
    }
}